Reply

Abstract

HepatologyVolume 38, Issue 6 p. 1593-1594 CorrespondenceFree Access Reply Gary L. Davis M.D., Gary L. Davis M.D. Division of Hepatology, Baylor University Medical Center, Dallas, TXSearch for more papers by this authorJanice Albrecht Ph.D., Janice Albrecht Ph.D. Schering-Plough Research Institute, Kenilworth, NJSearch for more papers by this authorJoann Harvey, Joann Harvey Schering-Plough Research Institute, Kenilworth, NJSearch for more papers by this authorJohn G. McHutchison M.D., John G. McHutchison M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, NCSearch for more papers by this authorMichael P. Manns M.D., Michael P. Manns M.D. Medizinische Hochschule Hannover, Division of Gastroenterology and Hepatology, Hannover, GermanySearch for more papers by this authorJohn B. Wong M.D., John B. Wong M.D. Division of Clinical Decision Making, Department of Medicine, Tufts-New England Medical Center, Boston, MASearch for more papers by this author Gary L. Davis M.D., Gary L. Davis M.D. Division of Hepatology, Baylor University Medical Center, Dallas, TXSearch for more papers by this authorJanice Albrecht Ph.D., Janice Albrecht Ph.D. Schering-Plough Research Institute, Kenilworth, NJSearch for more papers by this authorJoann Harvey, Joann Harvey Schering-Plough Research Institute, Kenilworth, NJSearch for more papers by this authorJohn G. McHutchison M.D., John G. McHutchison M.D. Duke Clinical Research Institute, Duke University Medical Center, Durham, NCSearch for more papers by this authorMichael P. Manns M.D., Michael P. Manns M.D. Medizinische Hochschule Hannover, Division of Gastroenterology and Hepatology, Hannover, GermanySearch for more papers by this authorJohn B. Wong M.D., John B. Wong M.D. Division of Clinical Decision Making, Department of Medicine, Tufts-New England Medical Center, Boston, MASearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1016/j.hep.2003.10.013AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645– 652. 2 This month from the NIH: HALT-C study. Hepatology 2002; 36: 792– 793. 3 Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131– 1137. 4 Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002; 122: 1303– 1313. 5 Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet. 2001; 358: 958– 965. 6 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5: 431– 435. 7 The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20: 15– 20. Volume38, Issue6December 2003Pages 1593-1594 ReferencesRelatedInformation